RxDoctor Payments Data
★ My doctorsLook up a doctor →

Eric Goldberg

Psychiatry · Destin, FLNPI 1679524946

Payments from drug & device makers

$208,038in general payments, 2019–2025

Across 667 payments — averaging $311.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$112K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$82K
  • Sunovion Pharmaceuticals Inc.$3K
  • MDD US Operations, LLC$3K
  • AbbVie$1K
  • Johnson & Johnson$748
  • plus $5K from 29 others

What the payments were for

  • Consulting fees$5,2803%
  • Speaking & faculty fees$164,70079%
  • Travel & lodging$20,00810%
  • Food & beverage$18,0499%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Supernus Pharmaceuticals, Inc.146$112,233
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)198$82,157
Sunovion Pharmaceuticals Inc.20$3,438
MDD US Operations, LLC4$2,693
AbbVie(2 entities)82$1,488
Johnson & Johnson21$748
Axsome Therapeutics, Inc.21$669
Lundbeck LLC21$421
Jazz Pharmaceuticals Inc.16$404
Novo Nordisk5$391
AstraZeneca3$371
Idorsia Pharmaceuticals US Inc18$354
Takeda Pharmaceuticals U.S.A., Inc.18$313
Boston Scientific2$294
Otsuka America Pharmaceutical, Inc.15$286
Teva Pharmaceuticals USA, Inc.10$228
Eisai Inc.12$215
Neos Therapeutics, LP9$170
Vanda Pharmaceuticals Inc.4$151
Corium, LLC7$145
Biohaven Pharmaceuticals, Inc.1$125
E.r. Squibb & Sons, L.L.C.2$118
Alkermes, Inc.4$98
Ironshore Pharmaceuticals Inc.5$81
Indivior Inc.4$77
Tris Pharma Inc4$66
Almatica Pharma LLC3$62
Avanir Pharmaceuticals, Inc.3$50
Merck2$43
Avadel CNS Pharmaceuticals, LLC1$33
Alfasigma USA, Inc.2$30
Neurocrine Biosciences, Inc.1$28
Grifols USA, LLC1$22
Shire North American Group Inc1$21
Arbor Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$208,038 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl22$10,416
VyvanseLisdexamfetamine Dimesylate11$4,199
Vilazodone Hcl18$1,993
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine56$1,552
Lamotrigine36$344
Escitalopram Oxalate17$317
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$310
Mirtazapine14$166
Zolpidem Tartrate31$146
Clonazepam18$109
Bupropion XlBupropion Hcl13$98
Alprazolam39$95
Trazodone Hcl13$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$313$4,19911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Destin

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →